Related Experiment Video
Updated: Oct 17, 2025

Standards for Quantitative Metalloproteomic Analysis Using Size Exclusion ICP-MS
Published on: April 13, 2016
Current and emerging mass spectrometry methods for the preclinical development of metal-based drugs: a critical
Maciej Jarosz1, Bernhard K Keppler2, Andrei R Timerbaev3
1Chair of Analytical Chemistry, Warsaw University of Technology, 00664, Warsaw, Poland.
Abstract:
This Trends article highlights the multiple ways in which the state-of-the-art molecular mass spectrometry can support the preclinical development of novel metal-based anticancer drugs. Examples from the recent literature-beyond routine characterization applications-are presented to illustrate what analytical and experimental design challenges are to be addressed to facilitate the translation of promising drug candidates to clinical practice.
Related Concept Videos
MALDI-TOF Mass Spectrometry
Matrix-assisted laser desorption ionization (MALDI) is a commonly...
Therapeutic Drug Monitoring: Drug Analysis Methods

